Less than two months after announcing its intention to expand operations in the United States, U.K.-based cell and gene therapy manufacturer OXB has acquired a viral vector manufacturing facility in North Carolina from National Resilience for $4.5 million. This strategic acquisition aligns with OXB’s broader goal of enhancing its production capabilities in the rapidly growing gene therapy sector.
The North Carolina facility is expected to bolster OXB’s capacity to meet increasing demand for viral vectors, which are critical components in the development of gene therapies. As the industry continues to evolve, companies like OXB are positioning themselves to capitalize on the expanding market, which is projected to see significant growth driven by advancements in personalized medicine and regenerative therapies.
This move not only underscores OXB’s commitment to establishing a stronger presence in the U.S. market but also highlights the competitive landscape among biopharmaceutical firms vying for dominance in the gene therapy arena. By enhancing its manufacturing footprint, OXB is better equipped to respond to client needs and accelerate the delivery of innovative therapies.
Start your 7-day trial and see what the database can do →
